Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Type Of Leukemia (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), By Treatment Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
Description
Leukemia Therapeutics Market Summary
The global leukemia therapeutics market size was estimated at USD 18.90 billion in 2024 and is projected to reach USD 36.02 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is expanding due to a rising global prevalence of acute and chronic leukemia across all age groups.
The growing adoption of precision oncology is enabling treatments tailored to genetic and molecular profiles, thereby improving patient outcomes. Advancements in diagnostic technologies are enabling earlier detection, which supports higher rates of treatment initiation. Pharmaceutical innovation in targeted therapies and immunotherapies is accelerating clinical adoption and shifting treatment standards. For instance, in April 2025, Frontiers in Medicine published a global burden study which reported that in 2021, there were approximately 461,422.7 leukemia incident cases, projected to reach 509,737.3 by 2031, and around 320,283.6 deaths in 2021 expected to rise to 344,694.3 by 2031, while DALYs declined from 10,982,836.2 to 10,785,356.1 during the same period.
Increasing survival rates are creating a larger population requiring long-term and sequential therapy. Strong R&D momentum supported by active clinical trials is introducing new therapeutic classes with improved efficacy. The commercial availability of combination regimens is further driving prescription volume and increasing therapy value.
The rapid penetration of targeted small-molecule drugs is transforming treatment strategies for AML, CLL, and ALL, delivering high response rates with manageable safety profiles. Continuous progress in kinase inhibitors, BCL-2 inhibitors, and monoclonal antibodies is driving a shift away from traditional chemotherapy. CAR-T therapies are gaining adoption due to their ability to achieve durable remission in patients with relapsed or refractory disease. For instance, in March 2025, Therapeutic Advances in Hematology reported a phase I trial in which 7 of 10 AML patients treated with anti-CLL-1 CAR-T achieved complete remission or CRi. All six who later underwent stem cell transplantation were alive at follow-up. At the same time, another trial showed three complete remissions among six patients receiving anti-CD38 CAR-T, with only grade 1-2 CRS and no ICANS events. Growing access to stem cell transplantation, wider use of oral regimens, and active label expansion strategies are strengthening long-term market growth.
Global Leukemia Therapeutics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global leukemia therapeutics market report based on type of leukemia, treatment type, distribution channel, and region:
The global leukemia therapeutics market size was estimated at USD 18.90 billion in 2024 and is projected to reach USD 36.02 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is expanding due to a rising global prevalence of acute and chronic leukemia across all age groups.
The growing adoption of precision oncology is enabling treatments tailored to genetic and molecular profiles, thereby improving patient outcomes. Advancements in diagnostic technologies are enabling earlier detection, which supports higher rates of treatment initiation. Pharmaceutical innovation in targeted therapies and immunotherapies is accelerating clinical adoption and shifting treatment standards. For instance, in April 2025, Frontiers in Medicine published a global burden study which reported that in 2021, there were approximately 461,422.7 leukemia incident cases, projected to reach 509,737.3 by 2031, and around 320,283.6 deaths in 2021 expected to rise to 344,694.3 by 2031, while DALYs declined from 10,982,836.2 to 10,785,356.1 during the same period.
Increasing survival rates are creating a larger population requiring long-term and sequential therapy. Strong R&D momentum supported by active clinical trials is introducing new therapeutic classes with improved efficacy. The commercial availability of combination regimens is further driving prescription volume and increasing therapy value.
The rapid penetration of targeted small-molecule drugs is transforming treatment strategies for AML, CLL, and ALL, delivering high response rates with manageable safety profiles. Continuous progress in kinase inhibitors, BCL-2 inhibitors, and monoclonal antibodies is driving a shift away from traditional chemotherapy. CAR-T therapies are gaining adoption due to their ability to achieve durable remission in patients with relapsed or refractory disease. For instance, in March 2025, Therapeutic Advances in Hematology reported a phase I trial in which 7 of 10 AML patients treated with anti-CLL-1 CAR-T achieved complete remission or CRi. All six who later underwent stem cell transplantation were alive at follow-up. At the same time, another trial showed three complete remissions among six patients receiving anti-CD38 CAR-T, with only grade 1-2 CRS and no ICANS events. Growing access to stem cell transplantation, wider use of oral regimens, and active label expansion strategies are strengthening long-term market growth.
Global Leukemia Therapeutics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global leukemia therapeutics market report based on type of leukemia, treatment type, distribution channel, and region:
- Type of Leukemia Outlook (Revenue, USD Million, 2021 - 2033)
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)
- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Others
- Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
- Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type of Leukemia
- 1.2.2. Treatment Type
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Leukemia Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- Chapter 4. Leukemia Therapeutics Market: Type of Leukemia Business Analysis
- 4.1. Type of Leukemia Market Share, 2024 & 2033
- 4.2. Type of Leukemia Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Type of Leukemia, 2021 to 2033 (USD Million)
- 4.4. Chronic Myeloid Leukemia (CML)
- 4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
- 4.5. Chronic Lymphocytic Leukemia (CLL)
- 4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021 - 2033 (USD Million)
- 4.6. Acute Lymphocytic Leukemia (ALL)
- 4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
- 4.7. Acute Myeloid Leukemia (AML)
- 4.7.1. Acute Myeloid Leukemia (AML) Market, 2021 - 2033 (USD Million)
- 4.8. Others
- 4.8.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 5. Leukemia Therapeutics Market: Treatment Type Business Analysis
- 5.1. Treatment Type Market Share, 2024 & 2033
- 5.2. Treatment Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by treatment type, 2021 to 2033 (USD Million)
- 5.4. Chemotherapy
- 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
- 5.5. Targeted Therapy
- 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
- 5.6. Immunotherapy
- 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 6. Leukemia Therapeutics Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacy
- 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacy
- 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 7. Leukemia Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Leukemia Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Treatment Type Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Treatment Type Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. U.S. Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Treatment Type Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Treatment Type Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Treatment Type Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Treatment Type Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Treatment Type Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Treatment Type Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Treatment Type Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Treatment Type Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Treatment Type Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Treatment Type Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Treatment Type Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Treatment Type Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Treatment Type Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Treatment Type Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Treatment Type Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Treatment Type Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Japan Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Treatment Type Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. China Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Treatment Type Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Treatment Type Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Treatment Type Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Treatment Type Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Pfizer Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Novartis
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Lupin Ltd.
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Amgen Inc.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. AbbVie
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Johnson & Johnson Services, Inc.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Bristol-Myers Squibb
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. F. Hoffmann-La Roche
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Takeda Pharmaceutical Co Ltd
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Sanofi/ Genzyme Corporation
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.